自己免疫性溶血性貧血治療の世界市場レポート 2025年

自己免疫性溶血性貧血治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.9%で19億9,000万米ドルに成長します。予測期間における成長の原動力は、世界的なAIHAの罹患率の上昇、標的治療に対する需要の増加、個別化医療の重視の高まり、自己免疫疾患研究への投資の拡大、発展途上国における医療アクセスの改善であると予測されます。予測期間中に予想される主な動向には、診断の技術的進歩、デジタルヘルスと遠隔医療の統合、標的治療の進歩、診断と薬剤開発におけるAIの利用、新たな免疫抑制アプローチの出現などが含まれます。

自己免疫疾患の有病率の上昇は、今後数年間の自己免疫性溶血性貧血治療市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内組織を攻撃し、炎症や組織損傷を引き起こすことで発症します。この罹患率の増加は、遺伝的感受性に大きく影響されており、遺伝的感受性によってこのような症状を発症する可能性が高まります。自己免疫性溶血性貧血の治療は、免疫系の活動によって引き起こされる赤血球破壊を最小限に抑えることで、これらの疾患を管理するために不可欠です。例えば、2023年5月、英国を拠点とする健康研究の推進を目的とする組織であるNational Institute for Health and Care Research（NIHR）は、自己免疫疾患は現在約10人に1人が罹患しており、19種類の自己免疫疾患が人口の約10％-13％の女性と7％の男性に影響を及ぼしていると報告しました。したがって、自己免疫疾患の発生が増加していることが、自己免疫性溶血性貧血治療市場の成長を促進しています。

自己免疫性溶血性貧血治療市場の主要企業は、画期的なモノクローナル抗体などの標的治療薬の開発を進めています。このモノクローナル抗体は、古典的補体系などの特定の免疫経路を選択的に遮断し、副作用を最小限に抑えながら赤血球破壊を抑えます。これらのモノクローナル抗体は、既存の治療法では対処できなかった独自のメカニズムや経路に関与する新規治療法です。例えば、2022年11月、フランスのヘルスケア企業であるSanofi S.A.は、古典的補体系のC1sタンパク質を阻害するモノクローナル抗体であるEnjaymo（スチムリマブ）の販売承認を欧州委員会から取得しました。この薬剤は、免疫系が健康な赤血球を攻撃して溶血を引き起こすまれな自己免疫疾患である寒冷凝集素病（CAD）の成人における溶血性貧血の治療に使用されます。Enjaymoは、この自己免疫性溶血性貧血の赤血球破壊を抑制する標的アプローチを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の自己免疫性溶血性貧血治療のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の自己免疫性溶血性貧血治療市場：成長率分析
• 世界の自己免疫性溶血性貧血治療市場の実績：規模と成長、2019～2024年
• 世界の自己免疫性溶血性貧血治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の自己免疫性溶血性貧血治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己免疫性溶血性貧血治療市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 温性自己免疫性溶血性貧血
• 寒冷性自己免疫性溶血性貧血
• その他
• 世界の自己免疫性溶血性貧血治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• コルチコステロイド
• 免疫抑制剤
• その他
• 世界の自己免疫性溶血性貧血治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射
• 経口
• その他
• 世界の自己免疫性溶血性貧血治療市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の自己免疫性溶血性貧血治療市場：温性自己免疫性溶血性貧血のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 原発性温性自己免疫性溶血性貧血
• 二次性温性自己免疫性溶血性貧血
• 世界の自己免疫性溶血性貧血治療市場：寒冷性自己免疫性溶血性貧血のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 原発性寒冷凝集素症（CAD）
• 二次性寒冷性自己免疫性溶血性貧血
• 世界の自己免疫性溶血性貧血治療市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 混合型自己免疫性溶血性貧血
• 発作性寒冷血色素尿症（PCH）
• 薬剤誘発性自己免疫性溶血性貧血

第7章 地域別・国別分析

• 世界の自己免疫性溶血性貧血治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の自己免疫性溶血性貧血治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己免疫性溶血性貧血治療市場：競合情勢
• 自己免疫性溶血性貧血治療市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Incyte Corporation
• Alexion Pharmaceuticals Inc.
• Hutchison China MediTech Limited
• BioCryst Pharmaceuticals Inc.
• Annexon Inc.
• Rigel Pharmaceuticals Inc.
• Nanjing IASO Biotherapeutics Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Momenta Pharmaceuticals Inc.
• Zenas BioPharma Inc.
• Immunovant Sciences GmbH
• Alpine Immune Sciences Inc.
• Agios Pharmaceuticals Inc.
• Kezar Life Sciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己免疫性溶血性貧血治療市場2029年：新たな機会を提供する国
• 自己免疫性溶血性貧血治療市場2029年：新たな機会を提供するセグメント
• 自己免疫性溶血性貧血治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autoimmune Hemolytic Anemia (AIHA) treatment consists of medications and therapies designed to prevent the immune system from destroying the body's own red blood cells. The primary goals of treatment are to decrease red blood cell destruction, alleviate symptoms of anemia, and avoid potential complications.

The main forms of autoimmune hemolytic anemia treatment include warm autoimmune hemolytic anemia, cold autoimmune hemolytic anemia, and other types. Warm autoimmune hemolytic anemia occurs when the immune system mistakenly attacks red blood cells at normal body temperatures, resulting in anemia. Treatment involves various classes of drugs such as corticosteroids, immunosuppressive agents, and other therapeutic options. These medications are delivered through several administration routes, including injectable, oral, and other methods. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The autoimmune hemolytic anemia treatment market research report is one of a series of new reports from The Business Research Company that provides autoimmune hemolytic anemia treatment market statistics, including the autoimmune hemolytic anemia treatment industry global market size, regional shares, competitors with the autoimmune hemolytic anemia treatment market share, detailed autoimmune hemolytic anemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune hemolytic anemia treatment industry. This autoimmune hemolytic anemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autoimmune hemolytic anemia treatment market size has grown strongly in recent years. It will grow from $1.30 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to greater awareness of the disease among healthcare professionals, an increasing prevalence of autoimmune disorders, expansion of hospital infrastructure, a rising number of published clinical studies, and a higher incidence of infections.

The autoimmune hemolytic anemia treatment market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The projected growth in the forecast period is expected to be driven by a rising global incidence of AIHA, increasing demand for targeted treatments, a growing emphasis on personalized medicine, expanding investment in autoimmune disease research, and improved healthcare access in developing countries. Key trends anticipated for the forecast period include technological progress in diagnostics, integration of digital health and telemedicine, advancements in targeted therapies, the use of AI in diagnostics and drug development, and the emergence of new immunosuppressive approaches.

The rising prevalence of autoimmune diseases is expected to drive the growth of the autoimmune hemolytic anemia treatment market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own tissues, resulting in inflammation and tissue damage. This growing prevalence is largely influenced by genetic susceptibility, which increases the likelihood of developing such conditions. Autoimmune hemolytic anemia treatments are vital in managing these disorders by minimizing red blood cell destruction caused by immune system activity. For example, in May 2023, the National Institute for Health and Care Research (NIHR), a UK-based organization dedicated to advancing health research, reported that autoimmune disorders now affect about one in ten individuals, with 19 different autoimmune diseases impacting approximately 10% of the population-13% of women and 7% of men. Therefore, the increasing occurrence of autoimmune diseases is driving the growth of the autoimmune hemolytic anemia treatment market.

Major companies in the autoimmune hemolytic anemia treatment market are advancing targeted therapies, such as first-in-class monoclonal antibodies, which selectively block specific immune pathways such as the classical complement system to reduce red blood cell destruction while minimizing adverse effects. These monoclonal antibodies represent novel therapies that engage unique mechanisms or pathways not previously addressed by existing treatments. For instance, in November 2022, Sanofi S.A., a healthcare company based in France, received marketing approval from the European Commission for Enjaymo (sutimlimab), a monoclonal antibody that inhibits the C1s protein in the classical complement pathway. This drug is used to treat hemolytic anemia in adults with Cold Agglutinin Disease (CAD), a rare autoimmune condition in which the immune system attacks healthy red blood cells, leading to hemolysis. Enjaymo provides a targeted approach to reducing red blood cell destruction in this form of autoimmune hemolytic anemia.

In October 2024, Recordati, a pharmaceutical company headquartered in Italy, acquired global rights to Enjaymo from Sanofi for $825 million. This acquisition is part of Recordati's strategy to strengthen its rare disease portfolio by securing a therapy for Cold Agglutinin Disease (CAD), a rare subtype of autoimmune hemolytic anemia, thereby enhancing its presence in the specialty pharmaceutical sector. Sanofi S.A. is a France-based biopharmaceutical company known for developing innovative treatments across diverse therapeutic areas.

Major players in the autoimmune hemolytic anemia treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., Hutchison China MediTech Limited, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Kezar Life Sciences Inc.

North America was the largest region in the autoimmune hemolytic anemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autoimmune hemolytic anemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autoimmune hemolytic anemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune hemolytic anemia treatment market consists of sales of monoclonal antibodies, complement inhibitors, blood transfusions, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autoimmune Hemolytic Anemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune hemolytic anemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autoimmune hemolytic anemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune hemolytic anemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Warm Autoimmune Hemolytic Anemia; Cold Autoimmune Hemolytic Anemia; Other Types
• 2) By Drug Class: Corticosteroids; Immunosuppressive Agents; Other Drug Classes
• 3) By Route Of Administration: Injectable; Oral; Other Route Of Administrations
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegment:
• 1) By Warm Autoimmune Hemolytic Anemia: Primary Warm Autoimmune Hemolytic Anemia; Secondary Warm Autoimmune Hemolytic Anemia
• 2) By Cold Autoimmune Hemolytic Anemia: Primary Cold Agglutinin Disease (CAD); Secondary Cold Autoimmune Hemolytic Anemia
• 3) By Other Types: Mixed-Type Autoimmune Hemolytic Anemia; Paroxysmal Cold Hemoglobinuria (PCH); Drug-Induced Autoimmune Hemolytic Anemia
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Sanofi SA; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autoimmune Hemolytic Anemia Treatment Market Characteristics

3. Autoimmune Hemolytic Anemia Treatment Market Trends And Strategies

4. Autoimmune Hemolytic Anemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autoimmune Hemolytic Anemia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autoimmune Hemolytic Anemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autoimmune Hemolytic Anemia Treatment Market Growth Rate Analysis
• 5.4. Global Autoimmune Hemolytic Anemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autoimmune Hemolytic Anemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autoimmune Hemolytic Anemia Treatment Total Addressable Market (TAM)

6. Autoimmune Hemolytic Anemia Treatment Market Segmentation

• 6.1. Global Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Warm Autoimmune Hemolytic Anemia
• Cold Autoimmune Hemolytic Anemia
• Other Types
• 6.2. Global Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Agents
• Other Drug Classes
• 6.3. Global Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Other Route Of Administrations
• 6.4. Global Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Autoimmune Hemolytic Anemia Treatment Market, Sub-Segmentation Of Warm Autoimmune Hemolytic Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Warm Autoimmune Hemolytic Anemia
• Secondary Warm Autoimmune Hemolytic Anemia
• 6.6. Global Autoimmune Hemolytic Anemia Treatment Market, Sub-Segmentation Of Cold Autoimmune Hemolytic Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Cold Agglutinin Disease (CAD)
• Secondary Cold Autoimmune Hemolytic Anemia
• 6.7. Global Autoimmune Hemolytic Anemia Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed-Type Autoimmune Hemolytic Anemia
• Paroxysmal Cold Hemoglobinuria (PCH)
• Drug-Induced Autoimmune Hemolytic Anemia

7. Autoimmune Hemolytic Anemia Treatment Market Regional And Country Analysis

• 7.1. Global Autoimmune Hemolytic Anemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autoimmune Hemolytic Anemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market

• 8.1. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autoimmune Hemolytic Anemia Treatment Market

• 9.1. China Autoimmune Hemolytic Anemia Treatment Market Overview
• 9.2. China Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autoimmune Hemolytic Anemia Treatment Market

• 10.1. India Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autoimmune Hemolytic Anemia Treatment Market

• 11.1. Japan Autoimmune Hemolytic Anemia Treatment Market Overview
• 11.2. Japan Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autoimmune Hemolytic Anemia Treatment Market

• 12.1. Australia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autoimmune Hemolytic Anemia Treatment Market

• 13.1. Indonesia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autoimmune Hemolytic Anemia Treatment Market

• 14.1. South Korea Autoimmune Hemolytic Anemia Treatment Market Overview
• 14.2. South Korea Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autoimmune Hemolytic Anemia Treatment Market

• 15.1. Western Europe Autoimmune Hemolytic Anemia Treatment Market Overview
• 15.2. Western Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autoimmune Hemolytic Anemia Treatment Market

• 16.1. UK Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autoimmune Hemolytic Anemia Treatment Market

• 17.1. Germany Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autoimmune Hemolytic Anemia Treatment Market

• 18.1. France Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autoimmune Hemolytic Anemia Treatment Market

• 19.1. Italy Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autoimmune Hemolytic Anemia Treatment Market

• 20.1. Spain Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market

• 21.1. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market Overview
• 21.2. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autoimmune Hemolytic Anemia Treatment Market

• 22.1. Russia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autoimmune Hemolytic Anemia Treatment Market

• 23.1. North America Autoimmune Hemolytic Anemia Treatment Market Overview
• 23.2. North America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autoimmune Hemolytic Anemia Treatment Market

• 24.1. USA Autoimmune Hemolytic Anemia Treatment Market Overview
• 24.2. USA Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autoimmune Hemolytic Anemia Treatment Market

• 25.1. Canada Autoimmune Hemolytic Anemia Treatment Market Overview
• 25.2. Canada Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autoimmune Hemolytic Anemia Treatment Market

• 26.1. South America Autoimmune Hemolytic Anemia Treatment Market Overview
• 26.2. South America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autoimmune Hemolytic Anemia Treatment Market

• 27.1. Brazil Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autoimmune Hemolytic Anemia Treatment Market

• 28.1. Middle East Autoimmune Hemolytic Anemia Treatment Market Overview
• 28.2. Middle East Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autoimmune Hemolytic Anemia Treatment Market

• 29.1. Africa Autoimmune Hemolytic Anemia Treatment Market Overview
• 29.2. Africa Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autoimmune Hemolytic Anemia Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autoimmune Hemolytic Anemia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Autoimmune Hemolytic Anemia Treatment Market Competitive Landscape
• 30.2. Autoimmune Hemolytic Anemia Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Autoimmune Hemolytic Anemia Treatment Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Incyte Corporation
• 31.3. Alexion Pharmaceuticals Inc.
• 31.4. Hutchison China MediTech Limited
• 31.5. BioCryst Pharmaceuticals Inc.
• 31.6. Annexon Inc.
• 31.7. Rigel Pharmaceuticals Inc.
• 31.8. Nanjing IASO Biotherapeutics Co. Ltd.
• 31.9. Apellis Pharmaceuticals Inc.
• 31.10. Momenta Pharmaceuticals Inc.
• 31.11. Zenas BioPharma Inc.
• 31.12. Immunovant Sciences GmbH
• 31.13. Alpine Immune Sciences Inc.
• 31.14. Agios Pharmaceuticals Inc.
• 31.15. Kezar Life Sciences Inc.

32. Global Autoimmune Hemolytic Anemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Hemolytic Anemia Treatment Market

34. Recent Developments In The Autoimmune Hemolytic Anemia Treatment Market

35. Autoimmune Hemolytic Anemia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Autoimmune Hemolytic Anemia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autoimmune Hemolytic Anemia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autoimmune Hemolytic Anemia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer